Table 3. KRAS mutational status of tumor tissue from metastatic colorectal cancer patients determined by multiplexed SCODA mutation detection assay vs. conventional quantitative PCR method.
| Patient | KRAS Mutation Status | |
|---|---|---|
| Multiplexed SCODA mutation detection | Conventional quantitative PCR | |
| SUCRC12 | G12D (41%) | G12D |
| SUCRC14 | G13D (0.04%) | WT |
| SUCRC16 | G12D (6.5%) | G12D |
| SUCRC21 | G12V (4.75%) | G12V |
| P004 | G12S (24%) | G12S |
| P008 | G12D (17%) | G12D |
| A007 | G12D (36%) | G12D |
| SUCRC24 | G13D (1.7%) | G13D |
| SUCRC17 | WT | WT |
| SUCRC26 | WT | WT |
| SUCRC27 | WT | WT |
| SUCRC18 | G13D (3.8%) | G13D |
| SUCRC13 | G12D (18%) | G12D |
| SUCRC20 | G12D (0.285%) | G12D |
| P001 | WT | WT |
| SUCRC15 | WT | WT |
| SUCRC19 | WT | WT |
| SUCRC22 | WT | Not analyzed |
| SUCRC23 | WT | WT |
Note: WT, wild-type.